Skip to main content

Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal

Written by Customer Service on . Posted in Public Companies.

BROOMFIELD, Colo., May 28, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today issued the following statement in response to the press release issued by Echo Lake Capital and its offer to acquire the Company for $4.00 per share in cash and contingent value rights:

Aclarion’s Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. We regularly review our strategic priorities and evaluate opportunities to enhance value for all stakeholders. To that end, the Board of Directors will carefully review and evaluate Echo Lake’s proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.

The Board authorized a share repurchase program underscoring our conviction that Aclarion’s current market valuation does not fully reflect the strength of our platform or the long-term opportunity ahead. This action also reflects our commitment to deploying capital in ways that serve the interests of all shareholders while continuing to invest in our business.

The Company notes that the Echo Lake communication contains numerous assertions regarding governance and other matters that lack important context and are presented in a manner that the Board believes is misleading. Aclarion’s Board comprises seven highly qualified directors with relevant expertise in healthcare, regulatory affairs, technology investing, payer contracting, public company leadership and scaling medical technologies. The Board is committed to ongoing Board enhancement and regularly evaluates its composition to ensure it brings the fresh perspectives and appropriate skills necessary to drive value creation for all Aclarion shareholders. Accordingly, five new directors have been appointed within the last six years, all of whom bring diverse perspectives that directly align with Aclarion’s strategic priorities.

Goodwin Procter LLP is serving as legal counsel for Aclarion.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains information that may constitute forward-looking statements, including with respect to Aclarion’s Board of Directors, Aclarion’s business strategy, and other matters. Forward-looking statements are not guarantees of future performance or results. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts and often use words such as “anticipate,” “estimate,” “expect,” “believe,” “will likely result,” “outlook,” “project” and other words and expressions of similar meaning. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the “Risk Factors” and related discussions in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and Aclarion undertakes no duty to update these statements.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jenna Shinderman
Sodali & Co
Jenna.shinderman@sodali.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.